Officials at Texas Tech University System’s Office of Technology Commercialization announce the signing of an exclusive worldwide license agreement for a chemical additive called an aptamer that makes certain existing antibiotics viable against antibiotic-resistant bacteria.
The agreement is with RI Scientific LLC for the development and commercialization of metallo-beta-lactamase inhibitors, short chains of nucleic acid that have demonstrated the ability to eliminate bacterial resistance to antibiotics.
“This technology is extremely important in terms of the number of people who can benefit from it,” said David L. Miller, vice chancellor for commercialization. “We believe that RI Scientific has the ability to work with a number of pharmaceutical companies through the clinical testing process to have the aptamers incorporated into many of the commonly used antibiotics that the medical community now depends on.”
The patented technology was developed by Robert W. Shaw, acting chairman of the Department of Chemistry and Biochemistry at Texas Tech, and Sung-Kun Kim, an assistant professor at Baylor University.
“The use of this aptamer may turn back the clock for many existing antibiotics that have lost their effectiveness due to the emergence of antibiotic-resistant bacterial strains,” Shaw said. “Beta-lactam antibiotics, such as penicillins and cephalosporins, account for billions of dollars in annual sales in the United States alone. Antibiotic-resistant bacteria present a major problem to the medical and pharmaceutical industries.”
When used in conjunction with these antibiotics, the aptamers overcome enzymes produced by resistant bacteria that allow them to survive exposure to antibiotics.
RI Scientific LLC is a biotechnology consulting company based in Cranston, R.I. It’s focused on discovering and commercializing drug therapeutics.
“We are looking forward to working with Dr. Shaw in our pre-clinical studies to validate this technology” said Gavin Scotti, chief executive officer of RI Scientific LLC. “We believe this technology holds the promise of helping many pharmaceutical companies maintain the effectiveness of drug portfolios they have spent many years and millions of dollars to develop.”
How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels
July 3rd 2025Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.